Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART Protocols in Adenomyosis (ADENOFERT)
NCT05937490Phase 4Unknown
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dienogest and leuprorelin extended-release injection in adenomyosis and infertility (4 arms), sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: Live birth after ART at 2 years. Status: unknown.
02
Drugs
dienogestleuprorelin extended-release injection
03
Conditions
adenomyosisinfertility
Beyond the preview
Go deeper on NCT05937490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05937490.